Dexrazoxane
- Generic Name
- Dexrazoxane
- Brand Names
- Savene, Totect, Zinecard
- Drug Type
- Small Molecule
- Chemical Formula
- C11H16N4O4
- CAS Number
- 24584-09-6
- Unique Ingredient Identifier
- 048L81261F
- Background
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
...
- Indication
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.
- Associated Conditions
- Doxorubicin Induced Cardiomyopathy, Drug Extravasation
- Associated Therapies
- -
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 73
- Registration Number
- NCT02584309
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Medical City Children's Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02519335
- Locations
- 🇺🇸
Medical City Children's Hospital, Dallas, Texas, United States
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
- Conditions
- Interventions
- Drug: VincristineDrug: DactinomycinDrug: CyclophosphamideProcedure: Surgical ResectionProcedure: RadiationDrug: Myeloid Growth FactorDrug: BevacizumabProcedure: Lymph Node SamplingDrug: SorafenibDrug: ^1^1C-methionineDrug: IrinotecanDrug: IfosfamideDrug: EtoposideDrug: Etoposide PhosphateDrug: DoxorubicinDrug: Dexrazoxane
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT01871766
- Locations
- 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸University of Florida Proton Therapy Institute, Jacksonville, Florida, United States
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT01864109
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT01596088
- Locations
- 🇯🇵
Japan, Tokyo and Other Japanese City, Japan
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
- Conditions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT01523977
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸UCSF, San Francisco, California, United States
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 642
- Registration Number
- NCT01231906
- Locations
- 🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 236
- Registration Number
- NCT00980460
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2019-02-19
- Target Recruit Count
- 1
- Registration Number
- NCT00928200
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.